Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

Autor: Carlo Bifulco, Gennaro Ciliberto, Franco Marincola, Bernard A. Fox, Giuseppe Masucci, Paolo A. Ascierto, G. Botti, Franck Pagès, M. Capone, Tilman T. Rau, Jérôme Galon
Přispěvatelé: Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Providence Portland Medical Center, Oregon Health and Science University [Portland] (OHSU), Karolinska University Hospital [Stockholm], Universität Bern [Bern] (UNIBE), Istituto Nazionale Tumori IRCCS, Sidra Medical and Research Center, Sidra Tower, Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, HAL UPMC, Gestionnaire, Universität Bern [Bern], Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Oregon Health & Science University [Portland] ( OHSU )
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Zdroj: Journal of Translational Medicine
Journal of Translational Medicine, BioMed Central, 2016, 14, pp.273. ⟨10.1186/s12967-016-1029-z⟩
Journal of Translational Medicine, 2016, 14, pp.273. ⟨10.1186/s12967-016-1029-z⟩
Journal of Translational Medicine, BioMed Central, 2016, 14, pp.273. 〈10.1186/s12967-016-1029-z〉
Galon, J; Fox, B A; Bifulco, C B; Masucci, G; Rau, Tilman; Botti, G; Marincola, F M; Ciliberto, G; Pages, F; Ascierto, P A; Capone, M (2016). Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. Journal of translational medicine, 14(273), p. 273. BioMed Central 10.1186/s12967-016-1029-z
ISSN: 1479-5876
Popis: International audience; The fifth “Melanoma Bridge Meeting” took place in Naples, December 1–5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient’s clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.
Databáze: OpenAIRE
Externí odkaz: